A groundbreaking, collaborative campaign bringing together the Cancer Research Institute, the leading nonprofit funder of immunotherapy research internationally, with the Israel Cancer Research Fund, North America’s largest nonprofit dedicated to supporting Israeli cancer research.
What is Immunotherapy?
Immunotherapy is a form of cancer treatment designed to empower a patient’s own immune system to detect and eliminate cancer cells anywhere in the body. New immunotherapeutic approaches have been used effectively for Hodgkin lymphoma, melanoma, lung, kidney, and bladder cancers, with clinical trials under way for more than 25 other types of cancer. Patients who respond to treatment have a higher likelihood of a sustained response since the immune system’s memory leads to longer-lasting protection.
How will it work?
A joint review panel consisting of members of CRI’s Scientific Advisory Council—which includes three Nobel Prize winners and which is led by Dr. Jim Allison, named one of TIME’s 100 most influential people for his pioneering work in cancer immunotherapy—and ICRF’s blue ribbon Scientific Review Panel will meet annually to vet and recommend funding for the most deserving immunotherapy investigations across the State of Israel.
Learn more about our partnership with the Israel Cancer Research Fund by downloading our info kit.